- Home
- OTLK vs NEN Comparison
OTLK vs NEN Comparison
Compare OTLK & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
NEN
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Company Overview
Basic Information| Metric | OTLK | NEN |
|---|---|---|
| Founded | 2010 | 1977 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 209.2M |
| IPO Year | 2016 | 1995 |
Fundamental Metrics
Financial Performance| Metric | OTLK | NEN |
|---|---|---|
| Price | $1.73 | $59.55 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 22.3M | 653.0 |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $8,146,123.00 | ★ $89,196,544.00 |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | ★ N/A | $19.68 |
| Revenue Growth | N/A | ★ 10.76 |
| 52 Week Low | $0.16 | $56.00 |
| 52 Week High | $3.39 | $74.00 |
Technical Indicators
Market Signals| Indicator | OTLK | NEN |
|---|---|---|
| Relative Strength Index (RSI) | 75.78 | 50.01 |
| Support Level | $1.60 | $56.83 |
| Resistance Level | $2.09 | $60.90 |
| Average True Range (ATR) | 0.22 | 0.81 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 88.79 | 60.29 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.